Kristie L. Kahl

Key Takeaways The Smart Stop trial showed a 96.7% complete response rate with a targeted therapy-first approach in LBCL, reducing chemotherapy reliance. Targeted therapy-first strategy maintained high response rates and did not compromise chemotherapy efficacy in LBCL patients. The trial highlighted the potential of targeted therapies to improve outcomes and reduce chemotherapy reliance in LBCL treatment. Future research will expand the trial to multiple sites and explore additional targeted therapies, aiming to refine treatment strategies for LBCL. SHOW MORE

Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.

Targeted therapy-first approach in LBCL may reduce chemotherapy need, maintaining high response rates and durability.

The FDA has granted approval to Rybrevant Faspro, the first and only subcutaneous therapy for EGFR-mutated non-small cell lung cancer.

Following her breast cancer diagnosis, Guerdy Abraira utilized genomic testing to gain clarity on her treatment path.

A large real-world analysis found that concurrent GLP-1 receptor agonist use was linked to significantly improved long-term survival and lower rates of irAEs in patients receiving ICIs.

Patients with cancer taking GLP-1 drugs alongside immunotherapy had better long-term survival and fewer immune-related side effects.

Patients were 9 times more likely to have little to no cancer remaining after their procedure with the apalutamide doublet compared with placebo plus ADT.

In a phase 3 study, Opdivo plus Yervoy did not improve overall survival when combined with chemotherapy for HER2-negative gastric or GEJ cancer.

Jeff Cape, a Blue Faery volunteer and HCC caregiver, shares why patient voices matter at ASCO and what he wishes every cancer patient knew.